CONMED (CNMD) raises 2019 revenue and earnings per share guidance.
CONMED Corporation (NASDAQ:CNMD) today announced that it will report financial results for the third quarter of 2019 after the market close on Wednesday, October 30, 2019. The Company's management will...
Below are the top five companies in the Health Care Equipment industry as measured by relative performance. This analysis was compiled based on yesterday's trading activity as we search for stocks that...
research report answers several questions (like current market status, future market opportunities, global and regional distribution) for stakeholders, primarily which market segments they should focus...
XRAY vs. CNMD: Which Stock Is the Better Value Option?
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services as well as robust margins despite intense competition.
The collaboration with GetWellNetwork is likely to allow Cerner (CERN) in enhancing functionality for clients and patients through third-party solutions.
Cerner (CERN) keeps its 2019 revenue guidance intact; expects improvement in bookings.
Strong international footprint, solid prospects in the global orthopedic space and an enhanced product pipeline bode well for Wright Medical (WMGI). However, adverse forex mars prospects.
SmarTrend identified an Uptrend for Conmed Corp (NASDAQ:CNMD) on December 31st, 2018 at $63.09. In approximately 9 months, Conmed Corp has returned 58.92% as of today's recent price of $100.26.
Nevro (NVRO) is gaining traction from a fortified international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
CONMED Corporation (NASDAQ: CNMD) announced today that LaVerne Council and Barbara Schwarzentraub are joining its Board of Directors. Ms. Schwarzentraub will join the Board effective immediately, with...
Fresenius Medical (FMS) aims to treat ESRD patients in remote locations of China.
PRA Health (PRAH) expects to enhance position and capabilities in the data and analytics field with the new tool, while simplifying treatment decisions.
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, contraction in gross margin remains a woe.
Accuray's (ARAY) CyberKnife delivers stereotactic body radiation therapy in only five sessions.
HMS Holdings (HMSY) can leverage VitreosHealth's prescriptive health insights that will enhance its growing and lucrative PHM suite.
OPKO Health (OPK) continues to gain from RAYALDEE and BioReference platforms, and solid R&D focus. However, operating losses remain a woe.
Patterson Companies (PDCO) continues to benefit from robust product portfolio, strong prospects in Animal Health unit and strategic buyouts. However, intense competition remains a woe.
SmarTrend identified an Uptrend for Conmed Corp (NASDAQ:CNMD) on December 31st, 2018 at $63.09. In approximately 9 months, Conmed Corp has returned 60.74% as of today's recent price of $101.41.